How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/homozygous-familial-hypercholesterolemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Homozygous Familial Hypercholesterolemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Homozygous Familial Hypercholesterolemia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Homozygous Familial Hypercholesterolemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Evkeeza	EVINACUMAB	Regeneron	Angiopoietin-like 3 Inhibitor [EPC]	Angiopoietin-related protein 3	2021-01-01
Caduet	Amlodipine Besylate	Pfizer Inc.	Dihydropyridine calcium channel blocker	L-type calcium channel
EVKEEZA	EVINACUMAB-DGNB	REGENERON PHARMACEUTICALS	Angiopoietin-like 3 Inhibitor [EPC]	Angiopoietin-related protein 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 1 drug in Homozygous Familial Hypercholesterolemia
REGENERON PHARMACEUTICALS · 1 drug in Homozygous Familial Hypercholesterolemia
Regeneron · 1 drug in Homozygous Familial Hypercholesterolemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Homozygous Familial Hypercholesterolemia:

Cite this brief

Drug Landscape (2026). Homozygous Familial Hypercholesterolemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/homozygous-familial-hypercholesterolemia. Accessed 2026-06-10.

Homozygous Familial Hypercholesterolemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing